Changes (mean change or change in proportion followed by 95% CI) in medical risk factors and cardioprotective medications in cardiovascular patients between IA, EOP and 6-month assessment
| From IA to EOP | From IA to 6 month follow-up | |||||||||
| n | IA | EOP | Change | P value | n | IA | 6 months | Change | P value | |
| Blood pressure (mm Hg) | ||||||||||
| Systolic blood pressure mean(SD) | 62 | 137.1±15.7 | 117.6±8.1 | −19.5 (−23.2, –15.8) | <0.001 | 54 | 137.3±15.9 | 119.9±11.5 | −17.7 (−22.5, –12.5) | <0.001 |
| Diastolic blood pressure mean (SD) | 62 | 75.9±9.3 | 73.7±8.3 | −2.2 (−5.2, 0.9) | 0.17 | 54 | 75.4±9.0 | 74.9±7.9 | −0.5 (−3.5, 2.5) | 0.76 |
| Blood pressure <130/80 (%) | 62 | 24 | 68 | 44 (27, 60) | <0.001 | 54 | 26 | 69 | 43 (25, 59) | <0.001 |
| LDL cholesterol | ||||||||||
| LDL (mmol/l) mean (SD) | 59 | 2.33±0.88 | 1.57±0.58 | −0.76 (−0.98, –0.54) | <0.001 | 37 | 2.18±0.76 | 1.71±0.74 | 0.47(−0.77, –0.16) | 0.004 |
| LDL <1.4 mmol/L (%) | 59 | 14 | 41 | 27 (14, 40) | <0.001 | 37 | 14 | 41 | 27 (5, 49) | 0.02 |
| HbA1c <53* (%) | 4 | 50 | 50 | 0 (−25, 25) | 1.00 | 3 | 67 | 67 | 0 (−33, 33) | 1.00 |
| Cardioprotective medications | ||||||||||
| Antiplatelets (%) | 64 | 91 | 91 | 0 (−2, 2) | 1.00 | 55 | 89 | 89 | 0 (−2, 2) | 1.00 |
| Beta blockers (%) | 64 | 67 | 66 | −1 (−6, 3) | 1.00 | 55 | 66 | 62 | −4 (−10, 30) | 0.50 |
| ACE inhibitors (%) | 64 | 36 | 36 | 0 (−9, 9) | 1.00 | 55 | 35 | 35 | 0 (−9, 9) | 1.00 |
| ARB’s (%) | 64 | 22 | 25 | 3 (−3, 9) | 0.5 | 55 | 25 | 31 | 6 (−2, 13) | 0.25 |
| Calcium channel blockers (%) | 64 | 19 | 22 | 3 (−3, 9) | 0.5 | 55 | 18 | 24 | 6 (−2, 2) | 0.25 |
| Statins (%) | 64 | 84 | 88 | 2 (−5, 11) | 0.63 | 55 | 82 | 82 | 0 (−11, 11) | 1.00 |
| Other lipid lowering medications (%) | 64 | 5 | 17 | 12 (3, 22) | 0.008 | 55 | 5 | 22 | 17 (5, 28) | 0.004 |
*In those with known diabetes.
ARBs, angiotensin II receptor blockers; EOP, end of programme; HbA1c, glycosylated haemoglobin; IA, initial assessment; LDL, low-density lipoprotein.